Remove 2016 Remove Competition Remove Physicians Remove Prospecting
article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

1] In a separate, controlled study, 80 percent of primary care physicians receiving micro-incentives referred patients to higher-value specialists they had never used before — representing a significant reduction in the total cost of care. Healthcare (2016), [link] [2] Parikh, R. million on orthopedic MS-DRGs.[1]

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

Pharma 52
article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Indeed, Amgen’s biosimilar was approved in September 2016, but the company was not able to launch it until January 2023 in the US. Biosimilar uptake could be more gradual.

Marketing 104